China Pharmaceutical Enterprises Transform to Healthcare Products Manufacturing
date：2017-03-15
browse：（862）
Keyword：
China pharmaceutical enterprises are struggling to survive in the competition and their market space are generally close to the development ceilings, whereas nutritious healthcare food still have great development potentials. Therefore, pharmaceutical enterprises have widely given attention to and started to enter the market of healthcare products.
China has over 200 A-share listed pharmaceutical enterprises and there are increasing pharmaceutical enterprises setting foot in the field of healthcare products in recent years. For example, Kangmei Pharmaceutical Co., Ltd. (600518.SH) announced in May 2015 that it would acquire 74% stock rights of Shenzhen Mckin Industry Co., Ltd. at the cost of RMB82.73 million, so as to enrich its varieties of healthcare products and expand its market of terminal consumer goods by means of integrating Mckin’s products and marketing channels.
Besides, many listed companies have separately disclosed their performance in the field of healthcare products.
Performance of Partial Listed Pharmaceutical Enterprises in the First Half of 2016
China has over 200 A-share listed pharmaceutical enterprises and there are increasing pharmaceutical enterprises setting foot in the field of healthcare products in recent years. For example, Kangmei Pharmaceutical Co., Ltd. (600518.SH) announced in May 2015 that it would acquire 74% stock rights of Shenzhen Mckin Industry Co., Ltd. at the cost of RMB82.73 million, so as to enrich its varieties of healthcare products and expand its market of terminal consumer goods by means of integrating Mckin’s products and marketing channels.
Besides, many listed companies have separately disclosed their performance in the field of healthcare products.
Performance of Partial Listed Pharmaceutical Enterprises in the First Half of 2016
| Company | Stock code | Change of operating revenue | Change of net profit | Relevant business of healthcare products and proportion | |
| Baiyun Mountain | 600332 | 3.60% | 8.89% | Comprehensive health | 43.30% |
| Kingworld Medicines | 01110HK | 13.75% | 41.20% | Healthcare products | 18.85% |
| JZJT | 600750 | -33.95% | 39.29% | Healthcare food and others | 12.63% |
| Zhejiang Medicine | 600216 | 23.16% | 46.78% | Human nutritional supplements | 12.41% |
| Tianmushan Pharmaceutical | 600671 | 17.64% | -34.12% | Healthcare products | 8.03% |
| Kangmei Pharmaceutical | 600518 | 23.59% | 22.91% | Healthcare food | 4.46% |
| Jointown Pharmaceutical | 600998 | 24.66% | 24.35% | Food, healthcare products and cosmetics | 4.43% |
| Harbin Pharmaceutical | 600664 | -22.17% | 2.09% | Healthcare products | 4.05% |
| Joincare | 600380 | 17.50% | -4.71% | Healthcare products | 2.95% |
| North China Pharmaceutical | 600812 | -12.00% | 24.43% | Vitamin and nutritious healthcare products | 2.89% |
| Neptunus Group | 000078 | 17.86% | 44.05% | Healthcare products and food | 2.84% |
| Renmintongtai Pharmaceutical | 600829 | -6.28% | 27.99% | Healthcare products | 0.65% |
The latest article
- White Paper on Bone and Joint Health of Chinese Consumers 2020
- Yili Dairy launched high-protein yogurt, focusing on sport people
- Sinopharm Xingsha launched the Japan's Champion probiotics
- China has introduced its first policy to support the industrial hemp industry
- Beyond Meat became the first overseas Artificial Meat company to set up a factory in China
- Nongfu Spring's market value exceeded HK $370 billion on its first day
- German infant nutrition brand Amykon launched two probiotics in China
- The revenue of Besunyoung in the first half year is about 610 million yuan
- Jellly candy and powder included in the health food filing dosage form in China
- H&H Group net profit increased by 9% for the first half of year
